SPHK2 and central nervous system cancer: Our observation that higher SPHK1 expression results in worse prognosis is in accordance with previous findings showing that increased SPHK1, but not SPHK2, correlates with lower progression-free survival in GB and has been associated with increased glioma grade [55,56].